Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-Release Lorazepam (EDG004) in GAD
NCT02305797Phase 3Completed
- Sponsor
- Edgemont Pharmaceuticals
- Start
- Jan 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lorazepam in generalized anxiety disorder (GAD), sponsored by Edgemont Pharmaceuticals. Started Jan 2015; status: completed.
02
Drugs
lorazepam
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT02305797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02305797.